⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RARE News
Ultragenyx Pharmaceutical Inc.
Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update
globenewswire.com
RARE
Form 8-K
sec.gov
RARE
Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH
globenewswire.com
CRVS
RARE
Form 8-K
sec.gov
RARE
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million
globenewswire.com
RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
accessnewswire.com
RARE
Form 8-K
sec.gov
RARE
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
globenewswire.com
RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
globenewswire.com
RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
accessnewswire.com
RARE